logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
6/24/2020 3:19:43 PM Acceleron Presents Topline Results Of PULSAR Phase 2 Trial Of Sotatercept In Patients With PAH
6/4/2020 4:11:13 PM Acceleron Appoints Christopher Hite To Its Board Of Directors
5/20/2020 7:16:19 AM Acceleron Announces Presentations On REBLOZYL At 2020 ASCO20 Virtual Scientific Program
5/19/2020 7:14:06 AM Acceleron Announces Oral Presentation Of PULSAR Phase 2 Trial Results In Virtual ATS 2020 Conference Session On June 24
5/4/2020 7:05:44 AM Acceleron Pharma: EMA Grants Priority Medicines Designation To Sotatercept
4/8/2020 7:08:23 AM Acceleron Receives FDA Breakthrough Therapy Designation For Sotatercept In Pulmonary Arterial Hypertension
1/27/2020 4:03:07 PM Acceleron Announces Sotatercept Achieved Primary And Secondary Endpoints In The PULSAR Phase 2 Placebo-Controlled Trial
1/23/2020 4:18:52 PM Acceleron Pharma Says John Quisel, EVP And Chief Business Officer, Is Leaving Company
12/30/2019 7:32:25 AM Acceleron And Fulcrum Therapeutics Announce Pulmonary Research And Discovery Collaboration Agreement
11/6/2019 7:59:25 AM Acceleron Pharma Q3 Net Loss $45.4 Mln, Revenue $4.2 Mln
9/9/2019 7:10:36 AM Acceleron Gets FDA Orphan Drug Designation For Sotatercept In Pulmonary Arterial Hypertension
8/5/2019 4:19:40 PM Acceleron Pharma Q2 Loss/share $0.34 Vs. Loss $0.63 Year Ago
6/26/2019 7:48:48 AM Acceleron Completes Target Enrollment In The PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension
4/5/2019 9:38:31 AM Celgene And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To FDA